GB201105991D0 - Anti-tumoural effects of cannabinoid combinations - Google Patents

Anti-tumoural effects of cannabinoid combinations

Info

Publication number
GB201105991D0
GB201105991D0 GBGB1105991.2A GB201105991A GB201105991D0 GB 201105991 D0 GB201105991 D0 GB 201105991D0 GB 201105991 A GB201105991 A GB 201105991A GB 201105991 D0 GB201105991 D0 GB 201105991D0
Authority
GB
United Kingdom
Prior art keywords
tumoural
cannabinoid combinations
effects
cannabinoid
combinations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
GBGB1105991.2A
Other versions
GB2478072B (en
GB2478072A (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GW Pharma Ltd
Otsuka Pharmaceutical Co Ltd
Original Assignee
GW Pharma Ltd
Otsuka Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GW Pharma Ltd, Otsuka Pharmaceutical Co Ltd filed Critical GW Pharma Ltd
Priority to GB1105991.2A priority Critical patent/GB2478072B/en
Priority claimed from GB0810195.8A external-priority patent/GB2471987B/en
Publication of GB201105991D0 publication Critical patent/GB201105991D0/en
Publication of GB2478072A publication Critical patent/GB2478072A/en
Application granted granted Critical
Publication of GB2478072B publication Critical patent/GB2478072B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
GB1105991.2A 2008-06-04 2008-06-04 Anti-tumoural effects of cannabinoid combinations Active GB2478072B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GB1105991.2A GB2478072B (en) 2008-06-04 2008-06-04 Anti-tumoural effects of cannabinoid combinations

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0810195.8A GB2471987B (en) 2008-06-04 2008-06-04 Anti-tumoural effects of cannabinoid combinations
GB1105991.2A GB2478072B (en) 2008-06-04 2008-06-04 Anti-tumoural effects of cannabinoid combinations

Publications (3)

Publication Number Publication Date
GB201105991D0 true GB201105991D0 (en) 2011-05-18
GB2478072A GB2478072A (en) 2011-08-24
GB2478072B GB2478072B (en) 2012-12-26

Family

ID=44072184

Family Applications (1)

Application Number Title Priority Date Filing Date
GB1105991.2A Active GB2478072B (en) 2008-06-04 2008-06-04 Anti-tumoural effects of cannabinoid combinations

Country Status (1)

Country Link
GB (1) GB2478072B (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2471523A (en) 2009-07-03 2011-01-05 Gw Pharma Ltd Use of tetrahydrocannibivarin (THCV) and optionally cannabidiol (CBD) in the treatment of epilepsy
TWI583374B (en) 2010-03-30 2017-05-21 Ｇｗ伐瑪有限公司 Use of the phytocannabinoid cannabidivarin (cbdv) in the treatment of epilepsy
GB2514054A (en) 2011-09-29 2014-11-12 Gw Pharma Ltd A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD)
GB2530001B (en) 2014-06-17 2019-01-16 Gw Pharma Ltd Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy
GB2527599A (en) 2014-06-27 2015-12-30 Gw Pharma Ltd Use of 7-OH-Cannabidiol (7-OH-CBD) and/or 7-OH-Cannabidivarin (7-OH-CBDV) in the treatment of epilepsy
GB2531282A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
GB2531281A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiol in the treatment of intractable epilepsy
GB2531278A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiol in the treatment of intractable epilepsy
GB2539472A (en) 2015-06-17 2016-12-21 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
GB2541191A (en) 2015-08-10 2017-02-15 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
GB2548873B (en) 2016-03-31 2020-12-02 Gw Res Ltd Use of Cannabidiol in the Treatment of SturgeWeber Syndrome
GB2551986A (en) 2016-07-01 2018-01-10 Gw Res Ltd Parenteral formulations
GB2551987A (en) 2016-07-01 2018-01-10 Gw Res Ltd Oral cannabinoid formulations
GB2553139A (en) 2016-08-25 2018-02-28 Gw Res Ltd Use of cannabinoids in the treatment of multiple myeloma
GB2557921A (en) 2016-12-16 2018-07-04 Gw Res Ltd Use of cannabinoids in the treatment of angelman syndrome
GB2559774B (en) 2017-02-17 2021-09-29 Gw Res Ltd Oral cannabinoid formulations
GB2569961B (en) 2018-01-03 2021-12-22 Gw Res Ltd Pharmaceutical
GB202002754D0 (en) 2020-02-27 2020-04-15 Gw Res Ltd Methods of treating tuberous sclerosis complex with cannabidiol and everolimus
US11160757B1 (en) 2020-10-12 2021-11-02 GW Research Limited pH dependent release coated microparticle cannabinoid formulations

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040039048A1 (en) * 2000-02-11 2004-02-26 Manuel Guzman Pastor Therapy with cannabinoid compounds for the treatment of brain tumors
ES1045342Y (en) * 2000-02-11 2001-02-16 Alvarez Manuel Couto ROTATING EXHIBITOR FOR POSTCARDS, PHOTOS AND SIMILAR.
US20080057117A1 (en) * 2002-02-15 2008-03-06 Forschungs Institut Miscia Verenfur Krebsforschung Pharmaceutical composition made up of cannibus extracts
US9084771B2 (en) * 2007-05-17 2015-07-21 Sutter West Bay Hospitals Methods and compositions for treating cancer

Also Published As

Publication number Publication date
GB2478072B (en) 2012-12-26
GB2478072A (en) 2011-08-24

Similar Documents

Publication Publication Date Title
GB2471987B (en) Anti-tumoural effects of cannabinoid combinations
GB2478074B (en) Anti-tumoural effects of cannabinoid combinations
GB2478072B (en) Anti-tumoural effects of cannabinoid combinations
GB2459968B (en) Efficiency-based determination of operational characteristics
TWI367207B (en) Substituted pyrrolidine-2-carboxamides
EP2332387A4 (en) Inter-threading indications of different types of communication
EP2275418A4 (en) Chromene compound
ZA201102604B (en) Alkylcyclohexylethers of dihydrotetraazabenzoazulenes
HK1156306A1 (en) Substituted dihydropyrazolones as inhibitors of hif-prolyl-4-hydroxylases hif--4-
EP2331089A4 (en) Uses of sesquiterpene derivatives
PL2133419T3 (en) Uses of cyanophycin beta-dipeptides
IL208281A0 (en) Substituted cyclohexyldiamines
HK1160925A1 (en) Use of athepsin
IL209175A0 (en) Substituted qunazolines
EP2341909A4 (en) Novel substituted azabenzoxazoles
EP2247531A4 (en) Reduction of silica
ZA201004979B (en) Extracts of sclerocarya birrea
EP2331490A4 (en) Preparation of dibutoxymethane
GB201114396D0 (en) Location of basesation
GB0820519D0 (en) Cryropreservation of erythrocytes
PL386302A1 (en) New derivative of isothiazolopyridine
GB0821710D0 (en) Derivatives of dihydroindolone
IL207009A0 (en) Extracts of sclerocarya birrea
PL383760A1 (en) New application of undecane-2-ol
PL383759A1 (en) New application of undecane-2-ol

Legal Events

Date Code Title Description
732E Amendments to the register in respect of changes of name or changes affecting rights (sect. 32/1977)

Free format text: REGISTERED BETWEEN 20230323 AND 20230329